Daily Wrap

The Deja Vu continues at the same level for the same reasons, euphoria over vaccine news, and with the same lack of follow through. SP-500 (30m) last time we were here was due to news about Gilead’s Remdesivir, which was positive news, but far from a game-changer. SP-500 (30m) since the Fed’s last stimulus program…